During the past decade, Changzhi People's Hospital conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Changzhi People's Hospital" #1 sponsor was "Beijing Tiantan Hospital" with 5 trials, followed by "BeiGene" with 2 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 2 trials sponsored, "Biohaven Pharmaceuticals, Inc." with 1 trials sponsored and "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 1 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Changzhi People's Hospital" #1 collaborator was "Changzhi People's Hospital" with 2 trials as a collaborator, "China-Japan Union Hospital, Jilin University" with 2 trials as a collaborator, "First Affiliated Hospital Xi'an Jiaotong University" with 2 trials as a collaborator, "Hainan People's Hospital" with 2 trials as a collaborator and "Huizhou Municipal Central Hospital" with 2 trials as a collaborator. Other collaborators include 138 different institutions and companies that were collaborators in the rest 144 trials.

According to Clinical.Site data, the most researched conditions in "Changzhi People's Hospital" are "Acute Ischemic Stroke" (2 trials), "Transient Ischemic Attack" (2 trials), "Acute Ischemic Stroke AIS" (1 trials), "Acute Migraine" (1 trials) and "Acute Stroke" (1 trials). Many other conditions were trialed in "Changzhi People's Hospital" in a lesser frequency.

Most popular intervention types in "Changzhi People's Hospital" are "Drug" (19 trials), "Combination Product" (1 trials), "Device" (1 trials), "Diagnostic Test" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Tislelizumab" (2 trials), "16S rRNA gene sequencing of cervical secretions" (1 trials), "Alteplase" (1 trials) and "Anti-PD-1 monoclonal antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "Changzhi People's Hospital" are 23 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Changzhi People's Hospital". 1 are not yet recruiting, 12 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Changzhi People's Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Changzhi People's Hospital, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".